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Abstract Adenosine A2B receptors of native human and
rodent cell lines were investigated using [
3H]PSB-298 [(8-
{4-[2-(2-hydroxyethylamino)-2-oxoethoxy]phenyl}-1-pro-
pylxanthine] in radioligand binding studies. [
3H]PSB-298
showed saturable and reversible binding. It exhibited a KD
value of 60 ± 1 nM and limited capacity (Bmax = 3.511 fmol
per milligram protein) at recombinant human adenosine
A2B receptors expressed in human embryonic kidney cells
(HEK-293). The addition of sodium chloride (100 mM) led
to a threefold increase in the number of binding sites
recognized by the radioligand. The curve of the agonist 50-
N-ethylcarboxamidoadenosine (NECA) was shifted to the
right in the presence of NaCl, while the curve of the
antagonist PSB-298 was shifted to the left, indicating that
PSB-298 may be an inverse agonist at A2B receptors.
Adenosine A2B receptors were shown to be the major
adenosine A2 receptor subtype on the mouse neuroblastoma
x rat glioma hybrid cell line NG108-15 cells. Binding
studies at rat INS-1 cells (insulin secreting cell line)
demonstrated that [
3H]PSB-298 is a selective radioligand
for adenosine A2B binding sites in this cell line.
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N-(2-{2-phenyl-6-[4-(3-phenylpropyl)-piper-
azine-1-carbonyl]-7H-pyrrolo[2,3-d]pyrimi-
din-4-ylamino}ethyl)acetamide
PSB-53 (4-(1-butyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-
purin-8-yl)-benzoic acid
PSB-297 (8-{4-[2-(2-hydroxyethylamino)-2-oxo-
ethoxy]phenyl}-1-propargylxanthine
PSB-298 (8-{4-[2-(2-hydroxyethylamino)-2-oxo-
ethoxy]phenyl}-1-propylxanthine
[
3H]PSB-
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[
3H]8-ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-
tetrahydro-1H-imidazo[2,1-i]-purin-5-one
PSB-1115 1-propyl-8-p-sulfophenylxanthine
ZM241385 (4-(2-((7-amino-2-(furyl)-1,2,4-triazolo[2,3-
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Introduction
Adenosine receptors are subdivided into four different
subtypes, A1,A 2A,A 2B and A3. Our knowledge of
adenosine A2B receptors lags behind that of the other
adenosine receptor subtypes because a lack of selective
pharmacological tools has hindered research in this area [1].
The adenosine A2B receptor subtype has recently attracted
considerable interest as a novel potential therapeutic target,
e.g., for anti-asthmatic, anti-diabetic, anti-diarrheal, anti-
Alzheimer, analgesic and anti-inflammatory drugs [2–5].
Radioligand binding assays are widely used for the
screening of new potential receptor ligands; they provide
data of the direct interaction between ligand and receptor
protein and, therefore, are ideally suitable for structure–
activity relationship analysis and molecular modeling
studies. In contrast, functional studies are only an indirect
indicator for the formation of a receptor–ligand complex.
Radioligands are also useful for the detection and quanti-
fication of receptor proteins in recombinant or native cell
lines or tissues. When we started this project, no selective
radioligand for adenosine A2B receptors was available; for
radioligand binding studies at adenosine A2B receptors, the
adenosine A1 receptor selective antagonist [
3H]DPCPX
([
3H]1,3-dipropyl-8-cyclopentylxanthine) or the adenosine
A2A receptor selective antagonist [
3H]ZM241385 ([
3H](4-
(2-((7-amino-2-(furyl)-1,2,4-triazolo[2,3-a]-1,3,5-triazin-5-
yl)amino)ethyl)phenol, see Figure 1) were frequently used,
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Figure 1 Structures of antago-
nist radioligands used for aden-
osine A2B receptor binding
assays
560 Purinergic Signalling (2006) 2:559–571but both radioligands are actually much more potent at
other adenosine receptor subtypes than at the adenosine
A2B receptor [6]. Further non-selective radioligands for the
labeling of adenosine A2B receptors have been used,
including [
125I]ABOPX ([
125I]3-amino-4-iodobenzyl-8-
phenyl-(4-oxyacetic acid)-1-propylxanthine) [7] and [
3H]-
DPX (1,3-diethyl-8-phenylxanthine) [8]. Jacobson et al.
developed [
3H]MRS1754 (N-(4-cyanophenyl)2-[4-(2,3,6,7-
tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy]
acetamide), the first potent and selective adenosine A2B
receptor antagonist radioligand (Figure 1)[ 9]. [
3H]-
MRS1754, however, is a very hydrophobic compound
showing only low solubility in water. Thus, the solution of
the radioligand added to the test tubes has to contain 50%
dimethylsulfoxide (DMSO) in order to allow constant
concentrations of the dissolved radioligand, and the final
DMSO concentration in the assays was 4.5% [9]. [
3H]-
MRS1754 exhibited a relatively high level of non-specific
binding of approximately 30% at a concentration of 0.7 nM
(KD = 1.13 nM) in Chinese hamster ovary (CHO) cells
expressing a very high level of >10 pmol of receptors per
milligram of protein [9]. Recently, Baraldi et al. developed
another potent and selective adenosine A2B receptor
antagonist radioligand, [
3H]MRE2029-F20 (N-benzo[1,3]-
dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahy-
dropurin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide)
for human adenosine A2B receptors [10–12]. The com-
pound was potent (KD 1.65 nM) and showed ca. 40-fold
selectivity versus human adenosine A1 receptors. So far it
has been used to detect only human, not rodent, A2B
receptors. Very recently, another adenosine A2B receptor
radioligand was described, [
3H]OSIP339391 (N-(2-{2-
phenyl-6-[4-(3-phenylpropyl)-piperazine-1-carbonyl]-7H-
pyrrolo[2,3-d]pyrimidin-4-ylamino}ethyl)acetamide with a
KD value of 0.17 nM [13]). The deazapurine derivative is
also as highly lipophilic and similarly bulky as the two
other adenosine A2B receptor selective radioligands
(Figure 1). Thus, [
3H]OSIP339391 can be used only in
the presence of 0.5% of bovine serum albumin to prevent
its adsorption to laboratory ware, e.g., vials, incubation
plates and pipette tips [13]. In addition, [
3H]OSIP339391
may label a second, low affinity, binding site in HEK-293
cells transfected with the human adenosine A2B receptor,
since the saturation assay showed a non-linear Rosenthal
plot. It has also only been investigated at human adenosine
receptor subtypes.
We have synthesized a new adenosine A2B receptor
antagonist ligand, [
3H]PSB-298, a polar compound with
relatively high water solubility, which exhibits a moderate
degree of non-specific binding and has been useful for the
testing of potential adenosine A2B receptor agonists and
antagonists in radioligand binding studies. Membranes
from HEK-293 cells expressing human adenosine A2B
receptors in a high density were used to evaluate the new
antagonist radioligand and to test its suitability for radio-
ligand binding studies at adenosine A2B receptors. Subse-
quently, three different cell lines were characterized using
[
3H]PSB-298 as an antagonist radioligand for adenosine
A2B receptors: a frequently used recombinant CHO cell line
expressing the human adenosine A2B receptor, a native
rodent mouse neuroblastoma x rat glioma hybrid cell line
(NG-108-15) and the rat insulinoma cell line INS-1. Using
[
3H]PSB-298 we have been able for the first time to
characterize the latter cell lines with respect to adenosine
A2B receptor expression in radioligand binding studies.
Materials and methods
Chemicals
Tris was obtained from Acros Organics (Leverkusen,
Germany), DMSO was from Fluka (Switzerland), HCl
was from Merck, HAT supplement from Gibco, [
3H]-
ZM241385 (17 Ci/mmol) was from Tocris; [
3H]MSX-2
([
3H]3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-
1-propargylxanthine) (84 Ci/mmol) [14], [
3H]PSB-11
[
3H]-8-ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-
1H-imidazo[2,1-i]-purin-5-one (53 Ci/mmol) [15] and [
3H]-
PSB-298 (124 Ci/mmol) were custom labeled by Amersham
from precursors that were synthesized in our laboratory as
described.[2,8-
3H]N
6-cyclopentyladenosine ([2,8-
3H]CHA)
(10–20 Ci/mmol) was from Moravek Biochemicals, Inc.,
Cal., USA; all other chemical reagents, cell culture materials
and adenosine receptor ligands were obtained from Sigma.
Synthesis of [
3H]PSB-298
Tritiated [
3H]PSB-298 was prepared by catalytic hy-
drogenation of the corresponding 1-propargyl derivative
(8-{4-[2-(2-hydroxyethylamino)-2-oxoethoxy]-phenyl}-1-
propargylxanthine (PSB-297) using tritium gas (custom
labeling). Unlabeled PSB-298 was synthesized as described
[16]. PSB-297 was prepared analogously starting from 6-
amino-3-propargyluracil [17]. The product PSB-297 was
purified by column chromatography on silica gel 60 using
dichloromethane:methanol [9:1 (v/v)] as the mobile phase.
Analytical data for PSB-297: mp, 295–297°C (decom-
position); MS, m/z (%) = 383.1 (M
+; 100); 365.1 (59);
282.1 (79); 253.1 (19); 85.1 (25). HRMS: found, 383.1221;
calculated, 383.1226; C18H17N5O5 (383.12).
1H-NMR: 3.04 (t, 1H, J = 2.2 Hz, C30H); 3.21 (quart,
2H, J = 6.0 Hz, CH2); 3.43 (t, 2H, J = 6.1 Hz, CH2); 4.55
(s, 2H, OCH2); 4.58 (d, 2H, J = 2.2 Hz, C10H2); 4.68(s,1H,
OH); 7.07 (d, 2H, J = 8.8 Hz, aryl CH); 8.01 (s, NH amide);
8.03 (d, 2H, J = 8.8 Hz, aryl CH); 12.03 (s, 1H, N3-H); 13.56
(s, 1H, N7-H).
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(HOCH2); 67.21 (OCH2); 72.02 (C30H); 80.93 (C20);
110.02 (C5); 115.00 (C300,C 5 00); 125.20 (C100); 127.46
(C200,C 6 00); 149.75 (C4); 151.34 (C8); 151.61 (C2); 155.42
(C6); 158.32 (C400); 167.69 (amide CO).
Purity confirmation by capillary electrophoresis: phos-
phate buffer containing 100 mM sodium dodecyl sulfate
(pH 7.4); voltage 10 kV; retention time 9.2 min; purity
100%; ultraviolet (UV) detection 318 nm; UV [methanol:
DMSO = 9:1 (v/v)] λmax1 = 246 nm, λmax2 = 318 nm;
solubility: soluble in dimethylformamide (DMF), DMSO,
hot methanol, hot methanol with water (80:20), slightly
soluble in cold methanol, cold ethanol and cold water. Rf
[silica gel plates Merck F254, dichloromethane:methanol =
9:1 (v/v)] 0.30 (compare Rf value of PSB-298 under the
same conditions: 0.32).
The radiolabeling was performed by Nycomed
Amersham, Buckinghamshire, UK through Amersham
Pharmacia Biotech Europe GmbH, Freiburg, Germany. The
specific activity of [
3H]PSB-298 was 124 Ci (4.59 TBq)/
mmol. UV spectroscopy (λmax = 318 nm, ɛ = 35,780) and
capillary electrophoresis with UV detection was used for
the quantification of [
3H]PSB-298 and for purity determi-
nation (see below).
Purity determination of [
3H]PSB-298
by capillary electrophoresis
Capillary electrophoresis was performed on a P/PACE
System 5500 (Beckman Coulter Instruments, Fullerton,
Calif., USA) equipped with a photodiode array detection
system. The instrument was controlled by P/ACE station
software (Beckman instruments). The runs were performed
under the following conditions: T = 25°C, λ = 321 nm, V =
10 kV, in 150 mM Tris-HCl buffer containing 100 mM
sodium dodecyl sulfate, pH 9.1. The electrophoretic
separations were carried out using an eCAP fused silica
capillary [75.0 μm internal diameter (I.D.) × 375 μm
outside diameter (O.D.), 37.0 cm length (30 cm to the
detector)]. The capillary was washed with 0.1 N aqueous
NaOH solution for 2 min, followed by deionized water for
1 min, and 150 mM Tris-HCl buffer containing 100 mM
sodium dodecyl sulfate, pH 9.1, for 1 min before each
injection. Injections were made by applying a slight
pressure (0.5 p.s.i.) for 5 s delivering approximately 5 nl
of the sample solution.
Stock solutions of the unlabeled compounds 8-[4-(2-
hydroxyethylamino)-2-oxoethoxy)phenyl-1-propylxanthine
(PSB-298) and 8-[4-(2-hydroxyethylamino)-2-oxoethoxy)-
phenyl-1-propargylxanthine (PSB-297) were prepared in
DMSO at a concentration of 1.0 mg/ml and were then
diluted with a mixture of DMSO and deionized water (1:1)
to obtain a range of different concentrations. The radioac-
tive compound [
3H]PSB-298 was dissolved in DMSO at a
concentration of 4.4 mg/ml and then diluted 1:1 with
deionized water. For the determination of linearity and the
limit of detection and quantitation, solutions of PSB-298
and PSB-297 were run in concentrations of 0.002 mg/ml,
0.005 mg/ml, 0.01 mg/ml, 0.02 mg/ml, 0.06 mg/ml,
0.08 mg/ml and 0.1 mg/ml. A high degree of linearity
was found in the range from their limit of quantitation
(LOQ; the lowest measured concentration within the linear
range) to the highest measured concentration of 0.1 mg/ml.
The regressive linearity coefficients for PSB-298 and PSB-
297 were 0.996 and 0.993, respectively. The LOQs for
PSB-298 and PSB-297 were 0.04 ± 0.001 mg/ml (SEM, n =
3) and 0.05 ± 0.002 mg/ml (SEM, n = 3), respectively. The
limit of detection (LOD) was defined as a signal-to-noise
ratio of 3. The LOD value for PSB-298 and PSB-297 was
0.002 mg/ml. Each sample was measured 3–4 times.
The concentration of the solution of [
3H]PSB-298 in
DMSO was determined by capillary electrophoresis. Peaks
were identified by two means: (1) by comparing the
migration times of the observed peak with that of the
non-radioactive PSB-298 eluted under the same conditions,
and (2) by spiking the radioactive sample with non-
radioactive PSB-298 standard. Under the same conditions
the peak for the precursor compound PSB-297 appeared at
6.31 ± 0.07 min and that for PSB-298 (radioactive and non-
radioactive) at 9.54 ± 0.13 min. The solution of the
radioactive compound gave only a single peak; no peak of
the starting compound was found, indicating high purity
(>95%). Therefore, quantitative determination could be
performed in the presence of PSB-297 (0.1 mg/ml) as an
internal standard.
Receptor-radioligand binding studies
HEK-293 cell membranes recombinantly expressing the
human adenosine A2B receptor (Bmax = 1.6 pmol per
milligram protein detected with [
3H]DPCPX) were pur-
chased from Perkin Elmer Life Sciences, Boston, USA.
CHO cells recombinantly expressing the human adenosine
A2B receptor were a gift from Dr. K.-N. Klotz and were
grown as described [18]. Membrane preparations were
obtained as described [18]. NG108-15 cells were provided
by Dr. Brüss, Pharmacological Institute, University of Bonn
and were grown as described [19, 20]. Membranes for
radioligand binding experiments were prepared by thawing
frozen cells followed by scraping them off the dishes in ice-
cold Tris-HCl buffer (50 mM Tris, pH 7.4). The cell
suspension was homogenized on ice and spun down for
10 min at 1,000 g at 4°C. After centrifugation of the
supernatant for 30 min at 20,000 r.p.m., the membrane
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pH 7.4) and centrifuged once more under the same
conditions. The protein concentration was determined by
the method of Lowry et al. using bovine serum albumin as
a standard reference [21]. The membranes were frozen at
−80°C at a protein concentration of 1–3 mg/ml until they
were used in the binding assays. INS-1 cells generously
provided by Dr. C.B. Wollheim (Geneva, Switzerland) were
grown in monolayer cultures (75 cm
2 culture flasks (5 ×
10
6 cells/20 ml) or 24-well culture plates (1.5 × 10
5 cells/
well) in RPMI 1640 medium supplemented with 10% (v/v)
foetal bovine serum, 10 mM HEPES, 2 mM glutamine,
1 mM pyruvate, 50 μM mercaptoethanol, 100 U/ml of
penicillin, and 0.1 mg/ml of streptomycin and cultured at
37°C in humidified 5% CO2/95% air.
Binding studies with [
3H]PSB-298 were performed in
Tris-HCl buffer (50 mM Tris, pH 7.4) containing adenosine
deaminase (1 U/ml) in a final volume of 200 μl. Stock
solutions of test compounds were made in DMSO; the final
DMSO concentrations did not exceed 1%. Non-specific
binding was determined in the presence of 1 mM 50-N-
ethylcarboxamidoadenosine (NECA). After 60 min of
incubation at room temperature (25°C) to allow equilibrium
to be reached, bound and free radioactivity were separated
by filtering the assay mixture through GF/B glass-fiber
filters using a Brandel cell harvester (Brandel, Gaithers-
burg, Md., USA). The filters were washed twice with 1 ml
ice-cold Tris buffer and the punched-out filters were
immediately transferred to mini-vials and incubated with
2.5 ml Ultima Gold scintillation cocktail (Canberra Packard)
for 9 h before being counted in a liquid scintillation counter
Tricarb 2100TR (Canberra Packard) with an efficiency of
65%. Two-to-four independent experimentswere performed.
Saturation studies at the recombinant adenosine A2B
receptors of HEK-293 cell membranes were performed in
duplicate using 50 μg of protein and were conducted over a
concentration range of 0.25 nM to 100–200 nM using
10–12 different concentrations of [
3H]PSB-298 (n = 3). For
saturation experiments at CHO and NG108-15 cell mem-
branes 100 μg of protein per assay were incubated in
duplicate with 10–12 different concentrations of the radio-
ligand in a concentration range of 0.25–200 nM (n = 2) and
0.3–300 nM (n = 4), respectively. Incubation conditions
were as described above. For kinetics studies and compe-
tition assays, 50 μg of recombinant protein and 1.0 nM
[
3H]PSB-298 were used. Association kinetics analysis was
conducted over a time range of 180 min with 14 different
time points; dissociation analysis was performed after
180 min of pre-incubation by the addition of 1 mM NECA
(final concentration) to initiate dissociation. Data reported
are means ± SEM of experiments performed in duplicate.
Binding studies with the adenosine A2A receptor
selective antagonist radioligand [
3H]MSX-2 in NG108-15
cells were performed in Tris-HCl buffer (50 mM Tris,
pH 7.4) containing adenosine deaminase (1 U/ml) in a final
volume of 1,000 μl and 100 μg of protein per vial. Non-
specific binding was determined in the presence of 50 μM
NECA. After 30 min of incubation at room temperature the
assay mixture was filtered through a GF/B glass-fiber filter
that had been pretreated for 1 h with a 0.3% polyethyleni-
mine solution using a Brandel cell harvester. The punched-
out filters were transferred to mini-vials and incubated with
2.5 ml of Ultima Gold scintillation cocktail (Canberra
Packard) for 6 h before being counted in a liquid
scintillation counter. The data were analyzed using Graph-
pad Prism (San Diego, Calif., USA), version 3.0. IC50
values were determined by fitting data to a sigmoidal curve
with variable slope. We used the equation built into the
program and chose standard weighting.
For the binding experiments at INS-1 cells half confluent
cells grown in 24-well culture plates were washed with
Krebs–Ringer–Hepes (KRH) buffer and thereafter incubat-
ed at 22°C with 20 nM [
3H]PSB-298 or 1 nM [2,8-
3H]CHA
with or without increasing concentrations of unlabeled
compounds, as indicated. The final incubation volume was
200 μl. To determine the non-specific binding, the
incubation was performed in the presence of 1 mM
unlabeled NECA. The incubation was terminated after
80 min (for [
3H]PSB-298) or 120 min (for [
3H]CHA) by
cooling (4°C) and washing twice with ice-cold KRH buffer.
After the buffer had been removed the pellet was lysed with
50 μl of 0.5% sodium dodecyl sulfate and counted in a
scintillation counter (TRI CARB 300 CD, Packard, Frank-
furt, Germany) with Quickscint 212, Zinsser Analytic
(Frankfurt, Germany). In these experiments at INS-1 cells
no adenosine deaminase was added.
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Purinergic Signalling (2006) 2:559–571 563Results
Preparation and physicochemical characterization
of [
3H]PSB-298
In a series of 1,8-disubstituted xanthine derivatives, which
had been optimized for high adenosine A2B receptor
affinity and selectivity, (8-{4-[2-(2-hydroxyethylamino)-2-
oxoethoxy]phenyl}-1-propylxanthine (PSB-298, Figure 2)
was identified as one of the most potent and most selective
adenosine A2B receptor antagonists (Ki = 1.2 nM vs [
3H]-
ZM241385 at recombinant human adenosine A2B receptors,
[16]). In addition, the compound is rather polar due to its
hydroxyethylamide structure and might therefore exhibit
only a moderate degree of non-specific binding. For these
reasons we decided to synthesize PSB-298 in tritium-
labeled form and investigate its usefulness as an antagonist
radioligand for adenosine A2B receptor binding studies.
[
3H]PSB-298 was prepared by catalytic hydrogenation of
the corresponding 1-propargyl derivative PSB-297 using
tritium gas (see Figure 2).
[
3H]PSB-298 was obtained with a high specific activity
of 124 Ci/mmol (4.59 TBq/mmol) and stored as a solution
in DMSO at a concentration of 4.4 mg/ml. Since the
compound was insoluble in solvents commonly used for
high performance liquid chromatography (HPLC) analysis,
micellar electrokinetic capillary chromatography combined
with UV detection was used for the purity determination
and quantification of [
3H]PSB-298. A typical electrophero-
Figure 3 Electropherogram of [
3H]PSB-298 in the presence of PSB-
297 as an internal standard. The separation conditions were 150 mM
Tris-HCl, 100 mM sodium dodecyl sulfate, pH 9.1, fused silica
capillary, 37 cm length (30 cm to the detector), 75 μM I.D.; 10 kV;
25°C; detection at 321 nm; pressure injection (0.5 p.s.i., 5 s)
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Figure 5 Kinetics of [
3H]PSB-298 binding (1 nM) to membranes
recombinantly expressing the human adenosine A2B receptor at 25°C.
A Association curve, B dissociation curve. Dissociation was initiated
by the addition of 1 mM NECA (final concentration) after 180 min of
pre-incubation. Experiments revealed a kinetic KD value of 25 nM.
Data points represent means from a typical experiment performed in
duplicates
Figure 4 UV spectrum of PSB-
298 (at a concentration of
0.01 mg/ml)
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3H]PSB-298 in the presence of its precursor PSB-
297, used as internal standard, is shown in Figure 3.
If [
3H]PSB-298 was injected alone, only a single
compound peak was observed; no impurities could be
detected (not shown), indicating a radiochemical purity of
>95%. The UV spectrum of PSB-298 is shown in Figure 4.
The absorption maximum at ca. 320 nm was used for
quantitative determination of the compound.
Characterization of [
3H]PSB-298 at recombinant
human adenosine A2B receptors
Commercially available membranes from HEK-293 cells
expressing the human adenosine A2B receptor in a high
density (Bmax value of 1.6 pmol per milligram protein) were
used to evaluate the new antagonist radioligand. Kinetics
studies were performed using 1 nM of [
3H]PSB-298. Both
association and dissociation appeared to be monophasic
(Figure 5). The equilibrium was reached after fewer than
5 min, and, after the addition of 1 mM NECA, the binding
could rapidly be reversed. A kinetic KD value of 25 nM was
calculated from the kinetic association and dissociation
constants. The equilibrium binding was stable for at least
180 min (not shown).
Saturation experiments demonstrated that [
3H]PSB-298
bound to a single class of binding sites in the HEK-293 cell
membranes recombinantly expressing the human adenosine
A2B receptor with a KD value of 60 ± 1 nM and an apparent
Bmax value of 3,511 ± 93 fmol per milligram protein
(Figure 6). A two-site model did not give an improved fit
over a one-site model. Control experiments with native
HEK-293 cells, which are known to endogenously express
a very low density of human adenosine A2B receptors did
not show any detectable specific binding of [
3H]PSB-298
(data not shown).
In competition assays a radioligand concentration of
1 nM and 50 μg of recombinant protein per tube in Tris
buffer pH 7.4 was employed. The use of a buffer of pH 6.4,
as described for [
3H]MRS-1754 [9], gave essentially
identical results. Pretreatment of the glass fiber filters with
polyethyleneimine was not required – it did not have any
effect on the amount of non-specific binding, which
amounted to 20–30% of total binding. Polypropylene and
glass tubes gave the same results. The presence of MgCl2
(10 mM), or EDTA (1 mM), or GTP (1 mM), respectively,
had no effect on the specific binding of 1 nM [
3H]PSB-298,
whereas the presence of NaCl led to a significant increase
in the specific binding of [
3H]PSB-298 in a concentration-
dependent manner (Figure 7). For example, in the presence
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of [
3H]PSB-298 binding to hu-
man adenosine A2B receptors
recombinantly expressed in
HEK-293 cells. The Scatchard–
Rosenthal plot of the saturation
binding experiment visualizes
the presence of one single class
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Figure 7 Effects of different
concentrations of sodium chlo-
ride on radioligand binding to
recombinant human adenosine
A2B receptors expressed in
HEK-293 cell membranes.
Membranes (50 μg) were incu-
bated for 60 min at 25°C with
1n M[
3H]PSB-298. Non-spe-
cific binding was determined
with 1 mM NECA. The data
are means of four independent
experiments ± SEM
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3H]PSB-298 was
more than doubled.
Competition experiments of the agonist NECA indicated
that the addition of 100 mM NaCl led to a rightward shift,
while the curve of the antagonist PSB-298 was shifted to
the left (Figure 8). In contrast, the addition of GTP (1 mM)
had no significant effect on the competition curve of NECA
(data not shown).
Ki values of standard adenosine receptor agonists and
antagonists were determined in radioligand binding assays
versus 1 nM [
3H]PSB-298; they were in accordance with
the Ki values described in the literature (Table 1, Figure 9).
NECA was more potent than 2-chloroadenosine and N
6-
cyclopentyladenosine. The rank order of antagonists was
CGS15943 (9-chloro-2-(2-furyl)[1,2,4]-triazolo[1,5c]china-
zoline-5-amine) >alloxazine >caffeine >theophylline.
In addition, another recombinant cell line (CHO) express-
ingthehumanadenosineA2B receptor was investigated. The
frequently used cell line was previously characterized in
adenylate cyclase assays due to its positive coupling to
adenylate cyclase via Gs protein [18]. Saturation experi-
ments with [
3H]PSB-298 confirmed the presence of
adenosine A2B receptors in the recombinant CHO cell line;
aK D valueof62±8nMandaBmax value of 561 ± 120 fmol
Table 1 Ki values for the displacement of [
3H]PSB-298 binding to
recombinant human adenosine A2B receptors expressed in HEK-293
cell membranes.
Compound Ki ± SEM [μM] Literature Ki ± SEM [μM]
Agonists
CADO 33.9 ± 2.7 25.5 ± 6.2
a
CPA 87.0 ± 0.5 20.6 ± 7.50
b; 34.4 ± 11.1
a; 21.1 ±
4.30
c; no inhibition at 5 μM
d
NECA 1.85 ± 0.15 0.570 ± 0.170
b; 0.33 ± 0.06
a;
0.361 ± 0.123
c; 0.489 ± 0.109
d
Antagonists
Caffeine 20.5 ± 2.2 10.4 ± 1.8
e
Theophylline 74.0 ± 16.0 15.2 ± 4.10
b; 9.07 ± 1.49
e; 15.2 ±
8.8
c; 17% inhibition at 10 μM
d
Alloxazine 1.34 ± 0.7 2.04 ± 0.57
b; 0.462 ± 0.078
c
CGS-15943 0.13 ± 0.01 0.0342 ± 0.001
b; 0.0164 ±
0.0036
c
a[7]; radioligand: [
125I]I-ABOPX.
b[9]; radioligand: [
3H]MRS 1754.
c[6]; radioligand: [
3H]ZM241385.
d[12]; radioligand: [
3H]OSIP339391.
e[22]; radioligand: [
125I]I-ABOPX.
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Figure 9 Competition experiments of the antagonists caffeine,
theophylline, alloxazine and CGS-15943 (a) and the agonists CADO,
CPA and NECA (b) versus 1 nM [
3H]PSB-298 performed at human
recombinant adenosine A2B receptors expressed in HEK-293 cells
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Figure 8 Effect of sodium chloride (100 mM) on the binding of the
antagonist PSB-298 and the agonist NECA, respectively, versus the
radioligand [
3H]PSB-298. Sodium shift experiments were performed
at human A2B adenosine receptors expressed in HEK-293 cell
membranes with 1 nM [
3H]PSB-298 and 50 μg of protein
566 Purinergic Signalling (2006) 2:559–571per milligram protein was determined (data not shown).
Experiments with different amounts of protein showed a
direct proportional relationship of the protein amount and
the specific binding of [
3H]PSB-298 (data not shown).
Based on these results, the new radioligand [
3H]PSB-
298 was subsequently used for characterizing two cell lines
believed to be natively expressing adenosine A2B receptors.
Characterization of NG108-15 cells with [
3H]PSB-298
The mouse neuroblastoma x rat glioma hybrid cell line had
previously been proposed to express adenosine A2A as well
as adenosine A2B receptors on the basis of functional assays
[20]. With the new adenosine A2B receptor radioligand, we
were now able to directly determine and quantify the
adenosine A2B receptor protein in the cell membranes.
Saturation experiments with [
3H]PSB-298 at membranes of
NG108-15 cells revealed a single class of binding sites with
aK D value of 226 ± 51 nM and a Bmax value of 453 ±
199 fmol per milligram protein (Figure 10).
The adenosine A2A receptor selective antagonist radio-
ligand [
3H]MSX-2 [14] showed no specific binding at
NG108-15 cell membranes; there was no significant
difference between total and non-specific binding (data
not shown). Thus, adenosine A2A receptors were not
detectable under the applied conditions of radioligand
binding studies.
Inhibition experiments using [
3H]PSB-298 at the rat
pancreatic beta cell line INS-1
The rat pancreatic beta cell line INS-1 was investigated
with respect to adenosine A2B receptor expression using
[
3H]PSB-298. We used this rodent cell line because of
further experiments concerning the influence of adenosine
receptor antagonists on insulin secretion in vitro and in
vivo. This is because our experiments have to be seen in the
context of diabetes, as is outlined later in more detail. We
tested the selectivity of the radioligand by trying to displace
[
3H]PSB-298 binding by rising concentrations of an
adenosine A1,A 2A or A3 receptor agonist (CHA,
CGS21680 and CI-IB-MECA, respectively). After an
increase of binding at low concentrations neither the A2A-
selective agonist CGS21680 nor the A3-selective agonist
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Figure 12 Inhibition of [
3H]PSB-298 binding to INS-1 cells by PSB-
53 and PSB-1115. INS-1 cells were incubated for 80 min at 22°C in
200 μl KRH buffer containing 5.6 mM glucose, 20 nM [
3H] PSB-298,
1 mM CHA (adenosine A1 receptor agonist) and increasing concen-
trations of indicated compounds (adenosine A2B receptor antagonists).
Results are expressed as percent of maximum specifically bound
radioactivity (non-specific binding in the presence of 1 mM unlabeled
NECAwas subtracted). Each value represents the mean ± SEM of five
separate experiments
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Figure 10 Saturation of [
3H]PSB-298 binding to native adenosine
A2B receptors in NG108-15 cells. The curve is representative of a
single experiment from four independent experiments performed in
duplicate
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Figure 11 Inhibition of [
3H]PSB-298 binding to INS-1 cells by CHA,
CGS-21680 and Cl-IB-MECA. INS-1 cells were incubated for 80 min
at 22°C in 200 μl KRH buffer containing 5.6 mM glucose, 20 nM
[
3H] PSB-298, and increasing concentrations of indicated compounds.
Results are expressed as percent of maximum specifically bound
radioactivity (non-specific binding in the presence of 1 mM unlabeled
NECAwas subtracted). Each value represents the mean ± SEM of five
separate experiments
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3H]PSB-298
binding. The A1-selective agonist CHA displaced the
radioligand only at rather high concentrations (100 μM)
(Figure 11).
Next, we investigated the selectivity of the A2B
antagonists PSB-1115 and PSB-53. We tried to displace
the A1 selective radioligand [
3H]CHA with increasing
concentrations of the adenosine A2B receptor antagonists.
None of them was effective in displacing; however
unlabeled CHA was effective as expected (data not shown).
Figure 12 shows the effects of the A2B antagonists PSB-
1115 and PSB-53 on [
3H]PSB-298 binding. Since the
radioligand [
3H]PSB-298 may interact with A1 binding
sites in addition to A2B binding sites, the experiments were
performed in the presence of the A1-selective ligand N
6-
cyclohexyladenosine (CHA). After an increase in binding at
low concentrations there was a sigmoidal inhibition of
binding in both cases. This displacement was complete at
100 μM. Both A2B antagonists were similarly potent. The
results were virtually identical when CHA was not present
during the experiments (data not shown).
Discussion
As a pharmacological tool to investigate adenosine A2B
receptors on the protein level, we synthesized a new
radioligand, [
3H]PSB-298, by catalytic hydrogenation of a
propargyl-substituted precursor. The radioligand showed
high specific radioactivity of 124 Ci/mmol. For the
characterization of the new antagonist radioligand [
3H]
PSB-298 saturation and kinetics studies in HEK-293 cells
recombinantly expressing the human adenosine A2B recep-
tor in high density were performed. With a kinetic KD value
of 25 nM and a KD value of 60 nM obtained in saturation
assays, [
3H]PSB-298 showed sufficiently high affinity and
appropriate kinetic and physicochemical properties to be
useful as an adenosine A2B receptor radioligand. This KD
value corresponded well with the Ki value of 58 nM for the
unlabeled PSB-298 determined with [
3H]PSB-298. It was
higher than the originally determined Ki value that had been
obtained in binding studies using the adenosine A2A
receptor selective radioligand [
3H]ZM241385 [16]. [
3H]
ZM241385 has been useful for the labeling of adenosine
A2B receptors in highly expressing artificial systems. The
reason for the discrepant results are currently unknown; one
explanation could be that both radioligands, which belong
to different structural classes of adenosine receptor antag-
onists, bind to somewhat different receptor sites or
conformations. Even though both compounds are antago-
nists at adenosine A2B receptors, they might label different
affinity states of the receptors. For example, antagonists
may be “neutral”, labeling all affinity states with the same
affinity, or “inverse agonistic,” binding preferably and with
higher affinity to the low-affinity state for agonists than to
the high affinity state for agonists [23]. Recently, it has
become clear that multiple conformational states of
G protein-coupled receptors (GPCRs) may exist that may
all exhibit somewhat different affinities for different ligands
[22]. The fact that the previously published data [16] were
of a more preliminary character (n = 2) may also contribute
to the discrepancy with the now thoroughly validated
values.
Competition experiments with a series of adenosine
receptor agonists and antagonists versus [
3H]PSB-298
revealed Ki values that were well in accordance with
literature data [6, 7, 9, 13, 24] (Table 1) proving that [
3H]
PSB-298 is a valuable tool for the identification of potential
ligands for the adenosine A2B receptor.
With a Ki value of 5 μM at human adenosine A2A
receptors [
3H]PSB-298 is highly selective for adenosine
A2B over A2A receptors [16]. Selectivity versus the human
adenosine A3 receptor is somewhat lower (Ki A3 422 nM,
[16]), but if used at a concentration of 1 nM, adenosine A3
receptors should not be labeled. However, PSB-298 is not
selective versus the adenosine A1 receptor at which it is
almost as potent as at adenosine A2B receptors (Ki 68 nM,
[16]). Thus, the new radioligand [
3H]PSB-298 may not be
superior to recently developed adenosine A2B receptor
radioligands [9, 10, 13] with respect to adenosine A2B
receptor selectivity. Nevertheless, it has other advantages,
including high polarity and good water solubility, low
molecular weight and moderate non-specific binding. The
non-specific binding amounted to 20–30% of total binding
at a radioligand concentration of 1 nM used in competition
assays in membranes expressing an A2B receptor density of
1.6 pmol per milligram of protein using 50 μg of protein in
200 ml TRIS buffer (50 mM, pH 7.4) containing no
additives. A direct comparison with published values for
non-specific binding of other radioligands is difficult, since
non-specific binding is dependent on (1) the concentration
of the radioligand, (2) the receptor density in the tissue, (3)
the protein concentration used, and (4) the incubation
conditions, buffer compositions, additives such as detergent
or bovine serum albumin, and other factors. In comparison,
the most polar of the other A2B radioligands described so
far, [
3H]OSIP-339391, has been reported to exhibit 20% of
non-specific binding at 1 nM concentration, but only in the
presence of 0.5% bovine serum albumin and in tissues
expressing an extremely high receptor density of 20 pmol
per milligram of protein [13]. The non-specific binding of
[
3H]MRS-1754 at a concentration of 0.7 nM was reported
to be less than 30% in membranes with a very high receptor
density of 10.9 pmol per milligram of protein [9]. [
3H]
MRE-2029-F20 showed 30–45% non-specific binding at its
KD value (1.65 nM) [12].
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receptor antagonist radioligands, [
3H]PSB-298 has no
tendency to bind to plasticware, and it is therefore easy to
handle without the necessity of preparing radioligand
dilutions in DMSO, including high DMSO concentrations
in the assays (as required for [
3H]MRS1754) or adding
bovine serum albumin (as required for [
3H]OSIP339391).
Sodium ions are well known for modulating the affinity
of agonists and antagonists for a number of GPCRs [25–
27]. Frequently, they lead to a decrease in the affinity of
agonists for the receptors and increase antagonist binding.
Adenosine A1 receptors [28] and adenosine A2A receptors
have been shown to be allosterically modulated by sodium
ions, presumably by binding of the sodium to aspartate 55
in the second transmembranal helix of the receptor protein
[29]. Gao et al. observed 2–27-fold rightward shifts of
agonist affinities in competition experiments at adenosine
A2A receptors, using the antagonist radioligand [
3H]-
ZM241385, upon addition of 1 M NaCl. Vogel et al.
recently showed that different salts, including sodium
chloride, are able to shift the equilibrium of metarhodopsin
from the inactive (MI) to the active (MII) state and act,
therefore, as allosteric modulators at this transmembrane
protein. The authors postulated that this influence of salts
on the conformation and stability may also apply to other
transmembrane proteins and, particularly, to other G protein-
coupled receptors [30].
In the present study we investigated the ability of sodium
ions to modulate agonist and antagonist binding to the
human adenosine A2B receptor. Sodium ions increased in a
concentration-dependent manner the specific binding of the
radioligand [
3H]PSB-298 to human recombinant adenosine
A2B receptors (Figure 7). A physiological concentration of
100 mM NaCl increased specific binding of the radioligand
by 245 ± 55%. A further increase in the NaCl concentra-
tion, up to 3 M NaCl, led to a further increase in specific
[
3H]PSB binding of up to 594 ± 116%. An EC50 value for
NaCl could not be determined, owing to its solubility limit.
In contrast, 100 mM NaCl had not shown any effect on
binding of the adenosine A2B receptor antagonist radio-
ligand [
3H]MRS1754 [9]. This may indicate that both
radioligands bind to different receptor conformations.
In the presence of 100 mM NaCl, which corresponds to
the extracellular physiological sodium concentration, the
competition curve of the adenosine receptor agonist NECA
was shifted to the right, whereas the competition curve for
the adenosine A2B receptor antagonist PSB-298 was shifted
to the left (Figure 8). The Na
+ shift (the ligand affinity in
the presence and absence of sodium ions) was previously
shown to be correlated with the intrinsic activity of ligands
at some GPCRs, including adenosine A2A receptors [27,
29]. Our results show that Na
+-shift experiments may also
be useful for the determination of the intrinsic activity of
ligands at human adenosine A2B receptors. While agonist
curves are shifted to the right in the presence of NaCl, the
observed left shift for the curve of PSB-298 may indicate
that it is an inverse agonist at adenosine A2B receptors.
NaCl shifts the equilibrium of receptor conformations to the
inactive state to which agonists exhibit reduced affinity but
inverse agonists exhibit increased affinity.
GTP usually results in an uncoupling of G protein-
coupled receptors from their G proteins and a conforma-
tional change from a high-affinity conformation for
agonists to a low-affinity conformation. In contrast, the
affinity for antagonists may be increased in the presence of
GTP [14, 31]. As previously observed for adenosine A2A
receptors, GTP also did not appear to exhibit a significant
effect on the conformation of adenosine A2B receptors. This
has been explained with an unusually tight coupling of the
adenosine A2A receptor with G proteins [32, 33]. The same
may be true for the adenosine A2B receptor.
The use of [
3H]PSB-298 allowed the direct evidence of
human adenosine A2B receptors expressed in CHO cells
that had been transfected and functionally characterized by
Klotz et al. [18]. The receptor density was considerably lower
thanintherecombinantHEK-293cells(561fmolpermilligram
protein vs 3,511 fmol per milligram protein). This explains why
previous attempts using [
3H]DPCPX or [
3H]ZM241385 to
label the adenosine A2B receptors in this recombinant cell line
had failed (own unpublished observations).
Mundell and Kelly had shown in functional assays that
the mouse neuroblastoma x rat glioma hybrid cell line
NG108-15 developed by Hamprecht [34], which is fre-
quently used as a model for neuronal cells, expressed two
different adenosine receptor subtypes, A2A and A2B [20].
Ohkubo et al. used reverse transcription polymerase chain
reaction to try to detect the mRNA for adenosine A2A and
A2B receptors with subtype-specific primers. With this
method, however, they only detected adenosine A2A but not
A2B message in NG108-15 cells [35]. In radioligand
binding studies using the new antagonist [
3H]PSB-298 we
have been able, for the first time, to detect adenosine A2B
receptors in this rodent hybrid cell line on the protein level.
We could show the predominance of the adenosine A2B
receptor in this cell line. Adenosine A2A receptors were not
detectable under the conditions of radioligand binding
studies using the adenosine A2A receptor antagonist radio-
ligand [
3H]MSX-2 [14]. These experiments suggest that the
expression level of adenosine A2B receptors is much higher
than that of adenosine A2A receptors in NG108-15 cells.
The radioligand binding studies revealed a KD value of
226 nM for [
3H]PSB-298 at the rodent adenosine A2B
receptors, showing an affinity that is approximately four-
times lower than the affinity to human adenosine A2B
receptors. Such a difference in the affinity for rodent and
human receptors has previously been observed for a series
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These studies showed that, although [
3H]PSB-298 has a
somewhat lower affinity for the rodent adenosine A2B
receptors than for the human adenosine A2B receptor
subtype, it can still be used as an adenosine A2B receptor
radioligand for the labeling of rodent adenosine A2B
receptors.
Thus, we used the radioligand for characterizing aden-
osine A2B receptors expressed on the rat pancreatic beta-
cell line INS-1. Adenosine A2B receptor antagonists have
been proposed as novel potential anti-diabetic drugs [1, 5].
Adenosine receptor subtypes have not been investigated in
detail with respect to diabetes: the involvement of adeno-
sine A1 receptors in insulin release [36] and the involve-
ment of adenosine A2 receptors with respect to glucagon
release [37] have been elucidated. Adenosine A2B receptor
antagonists are being developed for inhibiting hepatic
glucose production [5], to improve glucose tolerance and
to increase insulin sensitivity in skeletal muscle [38]. They
may also provide new drugs for the treatment of prolifer-
ative and diabetic retinopathy [39]. Therefore, we wanted to
investigate whether the adenosine A2B receptor antagonists
PSB-1115 and PSB-53, which are planned to be used in
animal experiments to study their anti-diabetic effects,
selectively bound to adenosine A2B receptors on the rat
pancreatic beta-cell line INS-1 using [
3H]PSB-298 as an
adenosine A2B receptor radioligand. In order to be close to
physiological conditions the radioligand binding assays
were performed at intact cells without the addition of
adenosine deaminase to degrade physiological adenosine.
The data showed that [
3H]PSB-298 labeled exclusively
adenosine A2B receptor binding sites, but not A1,A 2A or A3
receptors in INS-1 cells. Thus, the radioligand appears to be
selective for A2B receptors in these cells; however, at
present, it is not known whether the cells express enough
adenosine A2A and A3 subtype receptors to reveal full
selectivity. The IC50 values for PSB-53 and PSB-1115 were
in the low micromolar range and were, therefore, higher
than those determined in other binding assays where they
showed Ki values of 20–50 nM [16]. The same high
concentrations, however, were effective with respect to
insulin secretion in the same cell line (INS-1 cells).
Adenosine receptor agonist-induced inhibition of insulin
secretion was antagonized by PSB-1115 and PSB-53 at
micromolar rather than nanomolar concentrations (data not
shown), in accordance with the radioligand binding data.
As an agonist we used NECA, a non-degradable A2B
agonist, which is also a potent agonist at the other
adenosine receptor subtypes.
A high increase in binding was obvious at low
concentrations of either displacing compound versus [
3H]-
PSB-298. The increase in binding at low concentrations of
the displacing compound was highly reproducible. One
possible explanation for this behavior could be an allosteric
effect, as it has already been described for the A1 receptor
[40]. When we used CHA as an A1 receptor agonist in the
experiments, to avoid a possible interaction of the radio-
ligand with A1 binding sites, we obtained the same results.
Under our conditions [
3H]PSB-298 is a new and highly
selective radiolabel for adenosine A2B receptor binding
sites and is a valuable tool for adenosine receptor research.
Since the adenosine A2B antagonists tested are able to
antagonize NECA-induced inhibition of insulin secretion
(data not shown), the data obtained on adenosine A2B
receptor binding sites in INS-1 cells are likely to be
physiologically and pharmacologically relevant. The hith-
erto described characteristics of these adenosine A2B
receptor antagonistic compounds are not found in our
experiments, since the concentrations to be used are higher
than the EC50 values found in other cells. The concentration
of CHA half-maximally inhibiting [
3H]CHA binding in
INS-1 cells being in the range of 1 μM is much higher than
the previously observed Ki value for CHA at adenosine A1
receptors.
Conclusions
Recombinant (hA2B-HEK-293, hA2B-CHO cell mem-
branes) and native (NG108-15 cell membranes, INS-1
whole cells) human and rodent adenosine A2B receptors
were successfully characterized in radioligand binding
studies using [
3H]PSB-298 ((8-{4-[2-(2-hydroxyethyla-
mino)-2-oxoethoxy]phenyl}-1-propylxanthine), a new an-
tagonist radioligand. Modulation of radioligand binding by
sodium chloride allows for the characterization of agonists
and antagonists and, presumably, inverse agonists at
adenosine A2B receptors.
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